Cinacalcet

Block GA, Martin KJ, de Francisco AL et al (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350 1516-1525... [Pg.305]

Check parathyroid hormone (PTH), vitamin D and precursors, magnesium, and phosphate levels ° Pharmacological causes of decreased ionized calcium may include excess infusions of citrate, EDTA, lactate, fluoride poisoning, foscarnet, cinacalcet, bisphosphates, or unrelated increase in serum phosphate or decrease in serum magnesium levels... [Pg.161]

Cinacalcet is a calcimimetic that increases the sensitivity of receptors on the parathyroid gland to serum calcium levels to reduce PTH secretion. Cinacalcet maybe beneficial in patients with an increased Ca-P product who have elevated PTH levels and cannot use vitamin D therapy. Because the effects of cinacalcet on PTH can reduce serum calcium levels and result in hypocalcemia, cinacalcet should not be used if serum calcium levels are below normal. [Pg.391]

Cinacalcet reduces PTH secretion by increasing the sensitivity of the calcium-sensing receptor. The most common adverse events are nausea and vomiting. [Pg.883]

The most effective way to use cinacalcet with other therapies has not been decided. The starting dose is 30 mg daily, which can be titrated to the desired PTH and calcium concentrations every 3 to 4 weeks and to a maximum of 180 mg daily. [Pg.883]

Paricalcitol is a synthetically manufactured analogue of calcitriol. It is indicated for the prevention and treatment of secondary hyperparathyroidism in chronic kidney disease. Cinacalcet, a drug that acts as a calcimimetic, can be added if the effects on PTH levels are isufficient. [Pg.398]

Cinacalcet is a calcimimetic agent that modulates the response of the calciumsensing receptor on the parathyroid gland, and thus may lead to a reduction in the levels of calcium. It is marketed to treat hypercalcemia (Figure 8.83). [Pg.331]

Cinacalcet is the first representative of a new class of drugs that activates the calcium sensing receptor (CaR). CaR is widely distributed but has its greatest concentration in the parathyroid gland. Cinacalcet blocks PTH secretion by this mechanism and is approved for the treatment of secondary hyperparathyroidism in chronic kidney disease and for the treatment of parathyroid carcinoma. [Pg.964]

This rather common disease, if associated with symptoms and significant hypercalcemia, is best treated surgically. Oral phosphate and bisphosphonates have been tried but cannot be recommended. Asymptomatic patients with mild disease often do not get worse and may be left untreated. The calcimimetic agent cinacalcet, discussed previously, has been approved for secondary hyperparathyroidism and is in clinical trials for the treatment of primary hyperparathyroidism. If such drugs prove efficacious, medical management of this disease will need to be reconsidered. [Pg.968]

Cinacalcet Activates the calcium sensing receptor Inhibits PTH secretion Hyperparathyroidism Nausea... [Pg.975]

Parenteral (Calcimar, Miacalcin, Salmonine) 200 IU/mL for injection Cinacalcet (Sensipar)... [Pg.976]

Quarles LD Cinacalcet HCI A novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease. Kidney Int Suppl 2005 Jul(96) S24. [Pg.978]

Cinacalcet (Sensipar) [Hyperparathyroidism Agent/ Calcimimetic] Uses Secondary hyperparathyroidism in CRF T Ca2+ in parathyroid carcinoma Action 4- PTH by T Ca-sensing receptor sensitivity Dose ... [Pg.112]

Blizzard, RM, Chee, D and Davis, W, 1966, The incidence of parathyroid and other antibodies in the sera of patients with idiopathic hypoparathyroidism, Clin Exp Immunol 1 119-128 Block, GA, Martin, KJ, de Francisco, AL, Turner, SA, Avram, MM, Suranyi, MG, Hercz, G, Cunningham, J, Abu-Alfa, AK, Messa, P, Coyne, DW, Locatelli, F, Cohen, RM, Evenepoel, P, Moe, SM, Fournier, A, Braun, J, McCary, LC, Zani, VJ, Olson, KA, Drueke, TB and Goodman, WG, 2004, Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis, N Engl J Med 350 1516-1525... [Pg.160]

Dong BJ. Cinacalcet An oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther. 2005 27 1725-1751. [Pg.473]

See also in sourсe #XX -- [ Pg.112 ]

See also in sourсe #XX -- [ Pg.387 ]

See also in sourсe #XX -- [ Pg.332 , Pg.346 ]

See also in sourсe #XX -- [ Pg.469 ]

See also in sourсe #XX -- [ Pg.174 ]

See also in sourсe #XX -- [ Pg.73 ]

See also in sourсe #XX -- [ Pg.1072 , Pg.1072 ]

See also in sourсe #XX -- [ Pg.260 ]

See also in sourсe #XX -- [ Pg.284 ]

See also in sourсe #XX -- [ Pg.7 , Pg.24 ]

See also in sourсe #XX -- [ Pg.18 , Pg.20 , Pg.20 ]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...